Cell line · CVCL_0485
Papers103
2 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
1 to 20 of 103
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Multi-omics-driven personalized management of advanced HCC. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RNF180 loss stabilizes BCAS4 to enhance PD-L1 expression and immune evasion in hepatocellular carcinoma. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| FKBP52 dictates the dual role of p53 in hepatocellular carcinoma: Mutation-specific prognostic stratification and therapeutic implications. | J Biol Chem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Epigenetic silencing of the liver-specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TrxR1 inhibition sensitizes hepatocellular carcinoma to Motesanib via an autophagy-ROS-JNK/ER stress axis. | Biol Direct | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ISX-TWIST1 reprograms CD47-inflammasome signaling to reshape the immune microenvironment in liver cancer. | Exp Hematol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CCT2 Orchestrates Glycolysis and Exosome-Mediated M2 Macrophage Polarization in HCC tumorigenesis. | Int J Biol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Base Editing of TIGIT Reprograms CD155 Signaling in Natural Killer Cells to Enhance Cancer Immunotherapy Efficacy. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| H4K5 lactylation - ENO2 loop drives glycolysis and HCC progression. | JHEP Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| scResponse: A Rank-Based Method for Identifying Cell States That Contribute to Immunotherapy Response by Single-Cell Data. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RASGEF1B suppresses hepatocellular carcinoma through the ALDH7A1/Betaine/SNAI1 metabolic‒epigenetic axis. | J Transl Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Nutrient Restriction Improves the Therapeutic Efficacy of Sorafenib by Inducing Ferroptosis via the NRF2/HO-1/GPX4 Pathway in Hepatocellular Carcinoma. | J Hepatocell Carcinoma | 2026 | Its Methods give the RRID and name the line | PubMed | |
| NAT10 drives hepatocellular carcinoma progression through SQLE-mediated cholesterol biosynthesis and is targetable by remodelin. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Hepatocyte BPGM Induces RET Lactylation and Macrophage Reprogramming to Promote Tumorigenesis in Hepatocellular Carcinoma. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| DNMT2-m5C-ACLY Axis Promotes Lenvatinib Resistance in Hepatocellular Carcinoma Through Histone Acetylation-Mediated Notch Pathway. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Epithelial-Mesenchymal Transition and Stress Adaptations Underlie Yttrium-90 Resistance in Liver Cancer Cell Lines. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Menin-MLL1 complex cooperates with NF-Y to promote hepatocellular carcinoma survival. | Cell Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Disrupting DDB2-DNA Interaction by Lapatinib Enhances Chemotherapy Sensitivity. | Int J Biol Sci | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The LUBAC subunit HOIL-1 promotes the progression of HBV-associated hepatocellular carcinoma independently of linear ubiquitination. | Exp Mol Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| cGAS Inhibits ALDH2 to Suppress Lipid Droplet Function and Regulate MASLD Progression. | Adv Sci (Weinh) | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0485/papers